tiprankstipranks
Advertisement
Advertisement

PHVS Stock Latest News

Pharvaris Posts Q2 2026 Results as Deucrictibant Nears Key Phase 3 Data and Regulatory Milestones
Company AnnouncementsPharvaris Posts Q2 2026 Results as Deucrictibant Nears Key Phase 3 Data and Regulatory Milestones
4d ago
6K
PHVS
Pharvaris price target raised to $35 from $33 at BofA
PremiumThe Fly
Pharvaris price target raised to $35 from $33 at BofA
18d ago
PHVS
Pharvaris announces publication of review article on bradykinin
PremiumThe Fly
Pharvaris announces publication of review article on bradykinin
25d ago
PHVS
IBM downgraded, Cava upgraded: Wall Street’s top analyst calls
PremiumThe Fly
IBM downgraded, Cava upgraded: Wall Street’s top analyst calls
1M ago
AIG
AJG
Pharvaris initiated with an Overweight at Wells Fargo
PremiumThe Fly
Pharvaris initiated with an Overweight at Wells Fargo
1M ago
PHVS
Pharvaris Shareholders Approve 2025 Accounts and Renew Board Authorities at 2026 AGM
PremiumCompany AnnouncementsPharvaris Shareholders Approve 2025 Accounts and Renew Board Authorities at 2026 AGM
2M ago
6K
PHVS
Analyst Reiterates Buy on Deucrictibant’s Strong HAE Profile and Lifts Price Target to $46
Premium
Ratings
Analyst Reiterates Buy on Deucrictibant’s Strong HAE Profile and Lifts Price Target to $46
2M ago
PHVS
Pharvaris price target raised to $46 from $41 at Morgan Stanley
Premium
The Fly
Pharvaris price target raised to $46 from $41 at Morgan Stanley
2M ago
PHVS
Buy Rating Reiterated on Pharvaris with Unchanged $52 Price Target Ahead of Key Phase 3 Deucrictibant XR Readout
PremiumRatings
Buy Rating Reiterated on Pharvaris with Unchanged $52 Price Target Ahead of Key Phase 3 Deucrictibant XR Readout
2M ago
PHVS
Pharvaris Sets June 26, 2026 AGM as Late-Stage Angioedema Programs Advance
PremiumCompany Announcements
Pharvaris Sets June 26, 2026 AGM as Late-Stage Angioedema Programs Advance
2M ago
6K
PHVS
Pharvaris management to meet with Oppenheimer
PremiumThe Fly
Pharvaris management to meet with Oppenheimer
2M ago
PHVS
Pharvaris management to meet with Oppenheimer
PremiumThe Fly
Pharvaris management to meet with Oppenheimer
3M ago
PHVS
Pharvaris Maintained at Buy as Analyst Reaffirms $52 Price Target on Deucrictibant Late-Stage Strength and M&A Optionality
PremiumRatingsPharvaris Maintained at Buy as Analyst Reaffirms $52 Price Target on Deucrictibant Late-Stage Strength and M&A Optionality
3M ago
PHVS
Pharvaris price target raised to $33 from $31 at BofA
Premium
The Fly
Pharvaris price target raised to $33 from $31 at BofA
3M ago
PHVS
Pharvaris price target lowered to $74 from $75 at Citizens
Premium
The Fly
Pharvaris price target lowered to $74 from $75 at Citizens
3M ago
PHVS
Pharvaris reports Q1 EPS (EUR 0.59) vs. (EUR 0.85) last year
PremiumThe Fly
Pharvaris reports Q1 EPS (EUR 0.59) vs. (EUR 0.85) last year
3M ago
PHVS
Pharvaris Extends Cash Runway Into 2028 as Deucrictibant Nears Key Late-Stage Milestones
PremiumCompany Announcements
Pharvaris Extends Cash Runway Into 2028 as Deucrictibant Nears Key Late-Stage Milestones
3M ago
6K
PHVS
Pharvaris Raises $124 Million in May Equity Offering to Fund Late-Stage Programs and U.S. Commercial Build-Out
PremiumCompany Announcements
Pharvaris Raises $124 Million in May Equity Offering to Fund Late-Stage Programs and U.S. Commercial Build-Out
3M ago
6K
PHVS
Pharvaris price target raised to $31 from $30 at BofA
PremiumThe Fly
Pharvaris price target raised to $31 from $30 at BofA
3M ago
PHVS
Pharvaris: Dual IR+XR Deucrictibant Strategy Supports Overweight Rating on Safety, Efficacy, and Differentiation
PremiumRatingsPharvaris: Dual IR+XR Deucrictibant Strategy Supports Overweight Rating on Safety, Efficacy, and Differentiation
4M ago
PHVS
Pharvaris presents data from deucrictibant IR capsule and XR tablet study
Premium
The Fly
Pharvaris presents data from deucrictibant IR capsule and XR tablet study
4M ago
PHVS
Pharvaris price target raised to $52 from $48 at JonesResearch
Premium
The Fly
Pharvaris price target raised to $52 from $48 at JonesResearch
4M ago
PHVS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >